The Medicines Co. (MDCO)

51.13
0.24 0.47
NASDAQ : Health Technology
Prev Close 50.89
Open 52.05
Day Low/High 49.16 / 52.22
52 Wk Low/High 16.69 / 58.48
Volume 1.38M
Avg Volume 2.20M
Exchange NASDAQ
Shares Outstanding 79.72M
Market Cap 4.26B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Medicines Company To Announce Fourth-Quarter And Full-Year 2018 Financial Results On February 27

The Medicines Company To Announce Fourth-Quarter And Full-Year 2018 Financial Results On February 27

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, February 27, 2019, at 8:30 a.

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

Biotech and Beyond: 8 Favorite Healthcare Stocks for 2019

From small-cap genetics and biotech firms to large-cap drug distributors and pharmacies, eight experts select their top picks in the space for this year.

The Medicines Company Announces 5th Review Of Un-blinded Data And Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase 3 Trials

The Medicines Company Announces 5th Review Of Un-blinded Data And Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase 3 Trials

The Medicines Company (NASDAQ: MDCO) today announced that the 5 th review of un-blinded safety and efficacy data by the Independent Data Monitoring Committee (IDMC) for inclisiran Phase 3 trials has been completed.

MDCO: Insiders Vs. Shorts

MDCO: Insiders Vs. Shorts

The most recent short interest data was recently released for the 11/30/2018 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 15.65 "days to cover" versus the median component at 5.06. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

The Medicines Company Prices $150 Million Of Convertible Notes

The Medicines Company Prices $150 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $150 million in aggregate principal amount of its convertible senior notes due 2024.

The Medicines Company Announces Intention To Offer $150 Million Of Convertible Notes

The Medicines Company Announces Intention To Offer $150 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $150 million aggregate principal amount of convertible senior notes due 2024, subject to market conditions and other factors.

The Medicines Company Appoints Mark Timney As Chief Executive Officer

The Medicines Company Appoints Mark Timney As Chief Executive Officer

The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Mark Timney as the Company's new Chief Executive Officer and a member of the Board of Directors, effective immediately.

Company Profile For The Medicines Company

Company Profile For The Medicines Company

The Medicines Company is a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare.

The Medicines Company Reports Third-Quarter 2018 Results

The Medicines Company Reports Third-Quarter 2018 Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the third quarter ended September 30, 2018.

The Medicines Company To Announce Third-Quarter 2018 Financial Results On November 8

The Medicines Company To Announce Third-Quarter 2018 Financial Results On November 8

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Thursday, November 8, 2018, at 8:30 a.

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following Fourth Review Of Unblinded Data

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following Fourth Review Of Unblinded Data

The Medicines Company (NASDAQ:MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification.

The Medicines Company Reports Second-Quarter 2018 Results

The Medicines Company Reports Second-Quarter 2018 Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the second quarter ended June 30, 2018.

The Medicines Company To Announce Second-Quarter 2018 Financial Results On August 1

The Medicines Company To Announce Second-Quarter 2018 Financial Results On August 1

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, August 1, 2018, at 8:30 a.

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following [Third] Review Of Unblinded Data

The Medicines Company Announces Recommendation By Independent Data Monitoring Committee To Continue Inclisiran Phase III Trials Following [Third] Review Of Unblinded Data

The Medicines Company (NASDAQ: MDCO) today announced that the Independent Data Monitoring Committee (IDMC) for the ongoing inclisiran Phase III trials has recommended that the trials continue as designed and conducted, without modification.

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce The Potential Of The Medicines Company's Inclisiran In Patients With Diabetes

New Data Presented At The American Diabetes Association 78th Scientific Sessions® Reinforce The Potential Of The Medicines Company's Inclisiran In Patients With Diabetes

The Medicines Company (NASDAQ: MDCO) today announced the presentation of new data from a pre-specified, sub-group analysis of dosing, efficacy and safety of inclisiran in patients with diabetes from the ORION-1 Phase II trial at the American Diabetes...

The Medicines Company Announces Inclisiran Data Showing Significant Reductions In Potentially Harmful Subtypes Of Bad Cholesterol (Atherogenic Lipoproteins) Linked To Heart Attack And Stroke

The Medicines Company Announces Inclisiran Data Showing Significant Reductions In Potentially Harmful Subtypes Of Bad Cholesterol (Atherogenic Lipoproteins) Linked To Heart Attack And Stroke

The Medicines Company (NASDAQ:MDCO) today announced that the results of a pre-specified analysis of secondary endpoints from the ORION-1 Phase II study were presented at the 86 th European Atherosclerosis Society Congress (EAS 2018) and accepted for...

The Medicines Company Presents New Data At The National Lipid Association Scientific Sessions

The Medicines Company Presents New Data At The National Lipid Association Scientific Sessions

The Medicines Company (NASDAQ:MDCO) presented important new data and analyses from the ORION development program for inclisiran at the National Lipid Association (NLA) 2018 Scientific Sessions held in Las Vegas, NV.

First Week Of June 15th Options Trading For Medicines (MDCO)

Investors in Medicines Co saw new options become available this week, for the June 15th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MDCO options chain for the new June 15th contracts and identified one put and one call contract of particular interest.

The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company Reports First-Quarter 2018 Results

The Medicines Company (NASDAQ: MDCO) today reported its financial results for the first quarter ended March 31, 2018.

The Medicines Company To Announce First-Quarter 2018 Financial Results On April 25

The Medicines Company To Announce First-Quarter 2018 Financial Results On April 25

The Medicines Company (NASDAQ:MDCO) will host a conference call and audio webcast on Wednesday, April 25, 2018, at 8:30 a.

The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company Announces Chief Financial Officer Transition

The Medicines Company (NASDAQ: MDCO) today announced the appointment of Christopher Visioli as Chief Financial Officer and Treasurer of the Company, effective immediately.

The Medicines Company To Participate In The Oppenheimer 28th Annual Healthcare Conference

The Medicines Company To Participate In The Oppenheimer 28th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Oppenheimer 28 th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City, NY.

The Medicines Company Reaches Enrollment Target For ORION-10 Ahead Of Schedule

The Medicines Company Reaches Enrollment Target For ORION-10 Ahead Of Schedule

The Medicines Company (NASDAQ: MDCO) today announced that randomization of more than 1,500 patients in the ORION-10 trial in the United States has been completed in only 12 weeks - considerably beating its goal of 22 weeks.

The Medicines Company To Participate In The Cowen 38th Annual Health Care Conference

The Medicines Company To Participate In The Cowen 38th Annual Health Care Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Cowen 38 th Annual Health Care Conference on Tuesday, March 13, 2018, in Boston, MA.

The Medicines Company Appoints Dr. Sarah Schlesinger To Its Board Of Directors

The Medicines Company Appoints Dr. Sarah Schlesinger To Its Board Of Directors

The Medicines Company (NASDAQ: MDCO) today announced that its Board of Directors has appointed Dr.

The Medicines Company Reports Fourth-Quarter And Full-Year 2017 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full-Year 2017 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today reported its financial results for the fourth quarter and full year ended December 31, 2017.

The Medicines Company Reaches Enrollment Target For ORION-9 Ahead Of Schedule

The Medicines Company Reaches Enrollment Target For ORION-9 Ahead Of Schedule

The Medicines Company (NASDAQ: MDCO) today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks - considerably ahead of its anticipated recruitment goal of 24 weeks.

The Medicines Company To Host Conference Call And Webcast Discussing Fourth-Quarter And Full-Year 2017 Financial Results

The Medicines Company To Host Conference Call And Webcast Discussing Fourth-Quarter And Full-Year 2017 Financial Results

The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.

The Medicines Company To Participate In The Leerink Partners 7th Annual Global Healthcare Conference

The Medicines Company To Participate In The Leerink Partners 7th Annual Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) today announced that it will participate in the Leerink Partners 7 th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City.

Atlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round

Atlassian, AeroVironment, Granite Construction: 'Mad Money' Lightning Round

Jim Cramer focuses on Atlassian, AeroVironment, Granite Construction, Ford Motor, U.S. Concrete, Chesapeake Energy.